Metastatic Solid Tumor Clinical Trials in San Francisco, California

5 studies are recruiting for metastatic solid tumor in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #111, San Francisco, California

   Locations

   18 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06545942 on ClinicalTrials.gov

2. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

   This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #5, San Francisco, California

   Locations

   11 in total

   Run by

   Exelixis

   See if you can join NCT06952010 on ClinicalTrials.gov

3. Combination Therapy in Cancers With Mutations in DNA Repair Genes

   The purpose of this phase 1 clinical trials is to determine whether niraparib (a Poly (ADP-ribose) polymerase inhibitor (PARPi)) can be safely combined with irinotecan with manageable toxicity and reasonable efficacy. Emerging evidence suggest that PARPi is an effective therapeutic strategy in a wi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT05694715 on ClinicalTrials.gov

4. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

   The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   26 in total

   Run by

   Frontier Medicines Corporation

   See if you can join NCT06244771 on ClinicalTrials.gov

5. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov